The conversation about gut health in popular media has focused almost entirely on probiotics — the bacteria themselves. Take the right strains, repopulate the gut, improve health. It is a framing that has sold enormous quantities of supplements and contains a meaningful truth: the composition of the gut microbiome matters.
But the more important and more underappreciated story is what the bacteria do — specifically, what they produce when they ferment dietary fibre. Short-chain fatty acids (SCFAs) are the primary metabolic output of bacterial fermentation in the colon. They are fatty acids with fewer than six carbons, and they are, in the most literal sense, the language the gut speaks to the rest of the body.
Without adequate prebiotic fibre to ferment, the bacteria produce little. Without the right bacteria, the fibre goes unfermented. Without the SCFAs, the downstream benefits — intestinal barrier integrity, immune regulation, neurological function, metabolic health — are impaired regardless of how clean the diet is or how many probiotic supplements are taken.
The three SCFAs and what each does
60–70%
Acetate
Most abundant SCFA. Absorbed into systemic circulation and used as fuel by peripheral tissues including muscle and brain. Substrate for cholesterol synthesis in the liver. Acetate from gut bacteria reaches the brain and influences hypothalamic appetite regulation — directly contributing to satiety signalling.
20–25%
Propionate
Primarily metabolised in the liver — key regulator of hepatic glucose production (gluconeogenesis). Reduces liver fat production, improves insulin signalling, and directly signals satiety to the hypothalamus via the gut-brain axis. Lower in obese individuals and in those with type 2 diabetes.
10–15%
Butyrate ★
The most clinically significant. Primary fuel for colonocytes (colon cells — they derive 70% of their energy from butyrate). HDAC inhibitor — regulates gene expression throughout the body. Primary driver of intestinal barrier integrity. Crosses the blood-brain barrier and modulates neuroinflammation. Anti-cancer effects in colon well-documented.
Why butyrate is the most important molecule in gut health
Butyrate deserves its own section because its clinical significance extends far beyond the gut. It is simultaneously the primary fuel for colonocytes, a potent epigenetic regulator, the primary molecular guardian of intestinal barrier integrity, and a direct modulator of brain inflammation via the gut-brain axis.
These are not separate functions — they are facets of a single molecule with extraordinary biological range.
Butyrate — What It Does at Every Level
Colonocyte fuel
Colonocytes — the cells lining the colon — derive approximately 70% of their energy from butyrate rather than glucose. This is not a minor nutritional detail. It means the structural and functional integrity of the colonic epithelium is directly dependent on butyrate supply from bacterial fermentation. When dietary fibre falls — as it does on low-carbohydrate diets, ultra-processed food diets, or during illness and antibiotic use — colonocyte energy supply falls with it. The gut wall literally runs on bacterial by-products.
HDAC inhibition
Histone deacetylases (HDACs) are enzymes that condense DNA, silencing gene expression. Butyrate is the most potent endogenous HDAC inhibitor in the body — inhibiting HDACs increases gene expression across multiple anti-inflammatory, anti-cancer, and differentiation pathways. This is the epigenetic mechanism by which gut bacterial health influences gene expression throughout the body. HDAC inhibitors are under intensive pharmaceutical development as anti-cancer agents. The gut produces one endogenously — when adequately fed with fibre.
Intestinal barrier integrity
Butyrate drives the expression of tight junction proteins (claudin, occludin, zonulin) that maintain the physical seal between intestinal epithelial cells. Tight junctions control what passes from the gut lumen into systemic circulation. When butyrate production falls, tight junction integrity falls with it — producing the intestinal hyperpermeability (leaky gut) that allows bacterial endotoxins (LPS), undigested food antigens, and pathogens into the bloodstream. This is the most important single mechanism linking gut dysbiosis to systemic inflammation.
Neuroinflammation via gut-brain axis
Butyrate crosses the blood-brain barrier and directly modulates microglial function — microglia are the brain's resident immune cells, and their activation state drives neuroinflammation. Butyrate shifts microglia from a pro-inflammatory activated state toward a homeostatic anti-inflammatory state. In animal models, butyrate supplementation reverses cognitive deficits, reduces amyloid deposition, and improves depression-like behaviour. The clinical implication: gut dysbiosis → reduced butyrate → microglial activation → neuroinflammation is a direct mechanistic pathway from the gut to the brain.
Immune regulation
Butyrate promotes the differentiation of regulatory T cells (Tregs) — the immune cells responsible for immune tolerance and the prevention of autoimmunity. It suppresses the NF-κB inflammatory signalling pathway and reduces production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). This is the mechanism by which gut microbiome diversity and SCFA production are protective against autoimmune disease.
Metabolic effects
All three SCFAs improve insulin sensitivity and glucose regulation via multiple mechanisms: propionate reduces hepatic glucose production, acetate promotes glucagon-like peptide 1 (GLP-1) and peptide YY release from enteroendocrine cells (both are appetite-regulating hormones), and butyrate improves mitochondrial function in metabolic tissues. The GLP-1 connection is particularly relevant given the explosion of GLP-1 agonist drugs (Ozempic, Wegovy) — gut bacteria feeding on dietary fibre stimulate endogenous GLP-1 release via the same receptor system these drugs target.
Anti-cancer protection
The evidence for butyrate's protective role against colorectal cancer is among the strongest in the diet-cancer literature. Via HDAC inhibition, butyrate promotes differentiation and apoptosis of colonocytes — the normal programmed cell death that prevents accumulation of DNA mutations. Low dietary fibre → low butyrate → impaired colonocyte apoptosis is one mechanistic pathway from the low-fibre Western diet to the extraordinarily high colorectal cancer rates of modern populations.
Who produces butyrate and what they need
Butyrate is produced by a specific set of gut bacteria — primarily obligate anaerobes that are exquisitely dependent on the colonic environment and dietary conditions to survive. These are not the bacteria in most probiotic supplements, which tend to be Lactobacillus and Bifidobacterium species that are acid-tolerant and can survive manufacturing and gastric transit. The primary butyrate producers are anaerobes that cannot survive in oxygen and are genuinely difficult to deliver as conventional supplements.
Primary Butyrate-Producing Bacteria and Their Requirements
Faecalibacterium prausnitzii
The most abundant butyrate producer in the healthy human colon — comprising up to 5% of total gut bacteria. Consistently depleted in IBD, IBS, type 2 diabetes, obesity, depression, and colon cancer. Cannot be taken as a conventional probiotic — it cannot survive oxygen exposure. Requires: resistant starch, inulin-type fructans, arabinose-containing polysaccharides from plant foods.
Roseburia intestinalis
Major butyrate producer — depleted with low-carbohydrate diets. Particularly dependent on arabinoxylans (from wholegrains, particularly rye, wheat bran, and oats) and inulin. One of the first species to decline significantly when dietary fibre is reduced.
Eubacterium rectale
Produces butyrate via the acetyl-CoA pathway — different from the primary pathway used by most butyrate producers. Requires inulin-type fructans and resistant starch. Important cross-feeder — uses acetate from Bifidobacterium as substrate.
Clostridium butyricum
One of the few butyrate producers available as a probiotic — spore-forming, acid-resistant, commercially available in Japan and Europe. Evidence in IBD, IBS, and Clostridioides difficile prevention. The exception to the "butyrate producers can't be supplemented" rule.
Akkermansia muciniphila
Technically not a primary butyrate producer — it degrades mucin and its metabolites feed butyrate producers. Critical for cross-feeding in the colon. Depleted in obesity, metabolic syndrome, and multiple sclerosis. Now available as a commercial probiotic (Pendulum, Akkermansia Company).
What Depletes Butyrate Production
Low dietary fibre intake — the single most important factor. Less than 25g/day significantly impairs butyrate production. UK average intake is approximately 18g/day.
Antibiotics — broad-spectrum antibiotics dramatically reduce butyrate-producing bacteria. Recovery takes weeks to months. Repeated courses produce cumulative depletion.
Low-carbohydrate diets — even well-formulated ketogenic diets reduce fermentable substrate. The butyrate from dietary fat (ghee, butter) does not compensate for the bacterial fermentation route.
High red meat, low plant diet — the Western dietary pattern directly selects against butyrate-producing species and toward hydrogen sulphide-producing species associated with colorectal cancer risk.
PPIs (proton pump inhibitors) — alter the gastric acid environment in ways that change the bacterial composition reaching the colon, reducing butyrate producers.
Chronic stress — via the gut-brain axis, chronic HPA axis activation alters intestinal motility and mucosal immune function in ways that disadvantage butyrate producers.
The dietary strategy for SCFA production
The most important single dietary intervention for SCFA production is increasing dietary fibre — specifically the types of fibre that reach the colon intact for fermentation (prebiotics). Not all fibre is equally fermented, and not all fibre produces the same SCFAs.
Foods That Drive Butyrate and SCFA Production
| Food | Primary SCFA benefit | Target amount |
|---|
| Cooked and cooled potatoes, rice | Resistant starch RS3 — primary Faecalibacterium substrate | 1–2 servings daily |
| Unripe banana, green plantain | Resistant starch RS2 — rapidly fermented to butyrate | 1 daily |
| Oats (rolled, not instant) | Beta-glucan + arabinoxylan — Roseburia substrate | 40g daily |
| Legumes (beans, lentils, chickpeas) | Fermentable fibre mix — broad SCFA production | 3–4 servings weekly |
| Jerusalem artichoke, chicory root | Inulin-type fructans — highest concentration in diet | Moderate — high doses cause GI distress |
| Garlic, onion, leek | Fructooligosaccharides (FOS) — Bifidobacterium and cross-feeding | Daily inclusion |
| Wholegrains (rye, barley, wheat bran) | Arabinoxylan — primary Roseburia substrate | Replace refined grains |
| Apples, pears | Pectin — fermented to acetate and propionate | Daily |
| Asparagus, artichoke | Inulin + FOS — synergistic with garlic/onion | Regular inclusion |
| Ghee / butter (dietary butyrate) | Directly delivers butyrate but is absorbed in small intestine before reaching colon | Supplement — does not replace fermentation route |
When to test and what to look for
The GI-MAP stool test used in the TDG programme measures several markers directly relevant to SCFA status. The key indicators of impaired butyrate production are reduced Faecalibacterium prausnitzii (direct butyrate producer), elevated calprotectin (intestinal inflammation from compromised barrier function — the consequence of low butyrate), elevated LPS antibodies (bacterial endotoxin translocation — another consequence of barrier breakdown), and the overall pattern of commensal to pathobiont ratio.
The OAT additionally measures D-lactic acid and L-lactic acid — fermentation markers that indicate whether the gut microbiome is producing the expected mix of fermentation products. Elevated D-lactate is a marker of small intestinal bacterial overgrowth (SIBO) rather than healthy colonic fermentation.
The clinical picture that most reliably suggests impaired SCFA production is: low dietary fibre intake (usually apparent from dietary history), history of antibiotic use, gut dysbiosis on GI-MAP, elevated inflammatory markers (CRP, calprotectin), intestinal permeability markers positive, and — most importantly in the functional medicine context — the multi-system presentation that follows from impaired gut-brain signalling: depression or anxiety alongside gut symptoms, metabolic dysfunction alongside gut symptoms, immune dysregulation alongside gut symptoms. The gut is not a separate department. Its molecular output runs the rest of the body.
Want to know what your gut is actually producing?
The GI-MAP stool test maps your gut bacteria composition in clinical detail — including Faecalibacterium prausnitzii, intestinal permeability markers, calprotectin, and the full pathobiont picture. The OAT adds functional fermentation data.
GI-MAP Testing →
Related reading